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INTRODUCTION 
  Prostate cancer is the most common noncutaneous malignancy in men in 
the United States. In India, the  incidence is  relatively  less .Risk of 
disease varies most  prominently with age, ethnicity, family history, and 
diet . A strong family history   indicative of a highly penetrant prostate 
cancer gene is  believed to account  for only   5–10% of prostate cancers, 
whereas a larger  percentage  of prostate cancers may   be due to common 
polymorphisms in genes giving rise to a low penetrance risk of  disease1-3.  
Malignant transformation of prostate cells is accompanied by somatic   
genomic changes, including deletions, amplifications, and point 
mutations 4,5. In vitro studies of human prostate tissue have demonstrated 
that DNA adducts form in  prostate tissue after exposure to environmental 
toxins 6,7.  Moreover, intake of antioxidants via the diet or as supplements 
may decrease prostate cancer risk through the inactivation of reactive 
oxygen species, thereby protecting the DNA from oxidative damage 8.  
 This evidence suggests that DNA repair capacity may play an   
important role in prostate carcinogenesis, but little is known about what 
direct effect DNA repair capacity has on prostate cancer risk. 
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 XRCC1 is involved in DNA repair in the base excision repair 
pathway and appears to   play a scaffolding role in bringing together a 
complex of DNA repair proteins, including poly (ADP-ribose) 
polymerase (PARP), DNA ligase 3 (LIG3), and DNA polymerase 9 –11.    
Codons 194 and 399 contain polymorphisms that result in amino acid 
substitutions within evolutionarily conserved regions 12, 13.  Several studies 
have linked XRCC1 polymorphisms with biomarkers of DNA damage, 
including   aflatoxin   B1-DNA   adducts   and glycophorin  A variants in 
erythrocytes 14 , polyphenol-DNA adducts15 ,  and  DNA repair capacity in 
lymphocyte16. 
 The XPD gene codes for a DNA helicase involved in transcription 
and nucleotide excision repair. Mutations in the XPD gene can 
completely prevent DNA opening and dual incision, steps that lead to the 
repair of DNA adducts17 .   The DNA repair function of XPD is critical to 
reparation of genetic damage from tobacco and other carcinogens 18. 
Several common single bp substitution polymorphisms in the XPD    gene   
have been identified. 
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AIM AND OBJECTIVES 
 The  aim  of   the  study  is  to  determine  the   risk   attributed  by  
polymorphisms  in    genes  regulating  the  DNA  Repair pathway  with  
reference  to  the  Xray repair   Cross complementary 1 gene (XRCC1)   
and   Xeroderma pigmentosum  group D  gene   (XPD )   with  Carcinoma   
Prostate. 
  The  study  also  aims  to  perform  a  stratified   analysis  of   the  
genotypes with Age, Gleason  sum and Serum PSA  levels  of  Prostate  
Cancer patients. 
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REVIEW OF  LITERATURE 
EPIDEMIOLOGY 
Worldwide Incidence and Mortality 
 Prostate cancer is the fourth most common male malignant 
neoplasm worldwide. Its incidence varies widely between countries and 
ethnic populations, and disease rates differ by more than 100-fold   
between populations. The lowest yearly incidence rates occur in Asia (1.9 
cases per 100,000 in Tianjin, China) and the highest in North America 
and Scandinavia, especially in African Americans (272 cases per 
100,000)19. As in the United States, prostate cancer incidence has 
increased in many   countries since the early 1990s. Although much of the 
increase can be correlated with the introduction of PSA screening, some 
of the increase predates screening20. Mortality also varies widely among 
countries, being highest in Sweden (23 per 100,000 per year) and lowest 
in Asia (<5 per 100,000 per year in Singapore, Japan, and China). 
Mortality rates increased slowly for most countries between 1985 and 
1995 . 
 There are multiple complex causes for the worldwide and ethnic 
variations in prostate cancer incidence. Access to and quality of health 
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care, accuracy of cancer registries, and penetrance of PSA screening 
affect how rates of disease are reported.  Before reliable data were 
available from African countries, rates of prostate cancer in Africa   were 
thought to be much the same as those in Asia.  
 However, in Uganda and Nigeria, prostate cancer is common, and 
it is the most common cancer in men in Nigeria. Environment also plays 
an important role in modulating prostate cancer  risk  around  the  world. 
Japanese and Chinese men in the United States have a higher risk for 
development of prostate cancer and dying of  it than do their relatives in 
Japan and  China 21,22. Likewise, prostate cancer incidence and mortality 
have increased in Japan as the country has become more westernized 23.   
However, Asian Americans have a lower prostate cancer incidence than 
white or African American men do, indicating  that  genetics  still plays   
a  role   in  determining   prostate  cancer   predisposition. 
Age at Diagnosis  
 Prostate cancer is rarely diagnosed in men younger than 50 years, 
accounting for less than 0.1% of all patients. Peak incidence occurs 
between the ages of 70 and 74 years, with 85% diagnosed after the age of 
65 years24. At 85 years of age, the cumulative risk of clinically diagnosed 
prostate cancer ranges from 0.5% to 20%  worldwide, despite autopsy   
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evidence of microscopic lesions  in approximately  30%  of   men in the 
fourth decade, 50% of men in the sixth decade, and more than 75% of 
men older than 85 years25. PSA-based screening has induced an important 
age   migration effect; the incidence of prostate cancer  in  men 50 to  59 
years has increased  by 50% between 1989 and 199226 , with important     
implications for deciding  on  the  need  for, type  of,  and complications   
after  therapy. 
RISK FACTORS 
Familial and Genetic Influences 
 Ample epidemiologic evidence suggests that prostate cancer has 
both a familial and genetic component. The first reports of a familial 
clustering were published in the mid- 20th century and suggested that the 
risk for development of prostate cancer   was  higher  in  those  with   an   
affected   first-degree  relative 27 .  
 Subsequent case-control and cohort  studies have confirmed this 
observation28. Twin studies  have also suggested a genetic component, 
with higher rates of concordance for  monozygotic than for dizygotic 
brothers29,30  Relative risk increases according to the   number of affected 
family  members, their degree of  relatedness, and   the  age   at  which   
they  were  affected. 
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Familial and Genetic Influences 
Relative risk increases according to the number of affected family 
members, their degree of relatedness, and the age at which they were 
affected 
 
Family History Relative Risk Absolute Risk 
(%) 
None 1 8 
Father or brother 2 15 
Father or brother affected < 60 years 3 20 
Father and brother 4 30 
Hereditary prostate cancer 5 35-45 
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SUSCEPTIBLE GENES 
 Evidence for major prostate cancer susceptibility genes that 
segregate in families has been obtained from several complex segregation 
analyses, with the majority  supporting  a dominant and the remainder 
supporting a recessive or X-linked mode of inheritance31.  
At least eight candidate prostate cancer susceptibility  genes have 
been reported, including RNase L/HPC132, ELAC2/HPC233,  
SR- A/MSR134 ,  CHEK2 35  , BRCA2 36, PON137,  OGG138 , and MIC1 39. 
Individually, these genes are likely to account for only a small  fraction of 
the observed genetic predisposition to prostate  cancer. Other  segregation  
studies have suggested the existence of other prostate cancer  
susceptibility  loci on  chromosomes  1q42.2-43 (named PCAP)40  1p36 
(named CAPB,  also linked to brain tumors)41  and  Xq27-2842 , but the  
gene or genes linked to  these regions have not been identified. More 
recent genome- wide scans in larger cohorts of hereditary prostate cancer 
families have identified additional chromosomal loci linked to prostate 
cancer, and it is likely that the  number  of   known susceptibility  genes 
will  increase.  
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Prostate Cancer Susceptibility Genes 
Gene 
Chromosome 
Location 
Year  
Identified
Function 
ELAC2/HPC2 17p11 2001 Unknown 
RNase 
L/HPC1 
1q24-25 2002 Apoptosis and susceptibility 
to infection 
SR-A/MSR1 8p22-23 2002 Inflammation and 
susceptibility to infection 
OGG1 3p26.2 2002 DNA repair of oxidative 
damage 
CHEK2 22q12.1 2003 DNA damage signaling and 
cell cycle control 
BRCA2 13q12.3 2003 DNA repair 
PON1 7q21.3 2003 Antioxidant, free radical 
scavenger 
MIC1 19p13 2004 Inflammation 
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GENETIC ALTERATIONS   IN  PROSTATE CANCER 
Epigenetic changes 
 
 Epigenetic   events   affect  gene expression  without  altering the 
actual  sequence  of    DNA. Known   mechanisms   include   DNA   
hypermethylation   and  hypomethylation,   chromatin   remodeling,  
histone  modification,  and  RNA  interference  43 .  
 A variety of genes implicated in  prostate cancer initiation and 
progression  are affected  by these processes, including   
hypermethylation  of  hormonal response genes (AR,  ESR1, ESR2,  
RARB, and RARRES), genes controlling the cell cycle (CCND2 and   
CDKN2A), tumor cell invasion or tumor architecture genes (APC, CAV1, 
CD44, CDH1,  CDH13, LAMA3, LAMB3, and LAMC2), DNA repair 
genes  (GSTP1 and MGMT), signal  transduction genes (DAB2IP, 
DAPK1,  EDNRB, and RASSF1), and inflammatory  response genes 
(PTGS2);  hypomethylation of CAGE, HPSE, and PLAU; histone   
hypoacetylation of  CAR, CPA3, RARB, and vitamin D receptor; and  
histone  methylation   of  GSTP1 and PSA 44 .  
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 Clinical studies have shown  that quantitative methylation analysis 
of the GSTP1 gene   can  improve  sensitivity  and  specificity  for  the  
diagnosis  of  cancer, and efforts to  develop  global  gene  methylation  
profiles in serum, urine, and  tissue as  an  adjunct to   predicting risk of 
cancer, determining the need for repeated biopsy, and  demonstrating   
tumor aggressiveness  are underway 45  .    
 Furthermore,  agents  that   can inhibit  or  reverse  the  effects  of  
DNA Methyltransferases  and  histone  deacetylases   and restore normal 
gene  expression are under study for both prevention and therapy.  
Somatic   Mutations   associated  with  Tumor  Initiation  and  
Progression  
 A number of somatic mutations in tumor DNA are acquired during 
clonal  expansion of   nascent tumors as a result of mitotic errors, defects 
in DNA repair mechanisms, loss of  apoptotic ability, and other 
mechanisms. A variety of genes are so affected in prostate  cancer. 
Androgen Receptor  
 Polymorphisms of the androgen receptor are linked 
epidemiologically to prostate cancer risk.  Mutations  in  the  androgen  
receptor  gene  are  present  in about   50% of cancers and may cause 
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downregulation or loss of  receptor expression, production of hypoactive 
or hyperactive receptors, alteration of receptor-  ligand specificity, and 
conversion of androgen receptor antagonists to agonists, which  may 
confer a growth advantage and permit tumor progression 46.  
 Many of  the  growth  factors  and  tyrosine  kinases implicated in 
prostate cancer initiation  and progression may exert their effects through  
crosstalk  with androgen receptor47,48. Recent work in xenografts  
demonstrates  amplification  of androgen  receptor mRNA in  hormone-
refractory tumors, making “androgen-resistant” cells exquisitely sensitive 
to minute amounts of androgen49. This mechanism may underlie 
androgen resistance in men with end-stage disease, in which  tumor 
progression invariably occurs despite castrate serum levels, and it may 
also  explain some cases of  paradoxical  PSA declines after antiandrogen 
withdrawal  (antiandrogen withdrawal syndrome) 
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DNA  REPAIR  GENE  POLYMORPHISMS IN PROSTATE CANCER 
 No studies have examined the relationship between DNA repair 
capacity phenotypes and prostate cancer susceptibility, and only a few 
published studies on   DNA  repair genotypes and prostate cancer exist.   
Xu et al. studied 18 different   genetic variants of the DNA repair enzyme 
gene hOGG1, involved in base excision   repair, and found the genotype  
frequency of two sequence variants (11657A/G and Ser326Cys) was 
significantly different between prostate cancer  cases and controls.  They 
also confirmed the association with the 11657A/G variant in a family-
based association study.   
Van Gils et al.50  showed that  the XRCC1   codon Arg399Arg   
genotype was associated with elevated prostate cancer risk in those with 
low vitamin E or lycopene intake. In linking   genotypic risk with 
environmental exposure, the results of this study were consistent with the 
theory that  DNA  repair genes are most relevant in   situations of high 
mutagenic exposures. There are currently over 100 known DNA repair 
genes, and most are known to have  genetic variation in humans 51 . 
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 Rybicki et al examined the XRCC1  codon 399 and XPD codons 
312 and 751 polymorphisms in  relation to prostate cancer risk in a large 
sample of primarily. Only the XPD codon 312 Asn allele  showed a 
modest association with increased prostate cancer  risk, 60%, when two 
copies of the allele were present. Perhaps more revealing, however, was 
the potential interaction between the XPD codon 312 Asn  allele and the 
XRCC1 codon 399 Gln allele. When both alleles were present in their  
homozygous  states, the risk for prostate cancer increased 4.8-fold.   
 Whereas  genetic interactions are thought to be  more likely 
between genes involved in the same biological pathways, it is not 
unprecedented to find an increased  joint  effect between genes acting in 
different pathways. In the case of XRCC1 and  XPD, because   DNA 
damage caused by a mixture  of environmental exposures may   require 
either the base excision repair or nucleotide excision repair pathways, a   
reduction  in the efficiencies of only one of these pathways may not 
increase disease  risk to the same extent as when both pathways  are 
compromised. 
 Previous studies of the XRCC1 codon  399 polymorphism are 
equivocal with some finding increased  risk for the Gln allele 52,53   but 
others finding an increased risk for the Arg allele 54, 55 . 
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MATERIAL AND  METHODS 
Study  population    :     50  patients  who  either  attended  the Urology  
    Out patient Department or  those  admitted  in 
    Urology  ward   at   GGH, Chennai.   
Nature  of  Study     :  Retrospective  study 
No. of  Ca.Prostate  cases :  25  
No. of  Controls                :  25 
• BPH         : 19 
• Age matched  controls: 6                      
Study   Period                  :  November  2008  -  March 2011 
 The  age  of  the  subjects  included  in  the  study  ranged  from  55 
to  87  years. 
 The  cases  and  controls  were  similar  in  ethnicity  and  
nutritional  status. Clinical characteristics,  including Gleason score, PSA, 
and tumor stage were obtained   from the patients. The  controls  were  
healthy, unrelated  individuals  with  normal   serum  PSA  levels, normal  
digital rectal  examination . 
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OUTLINE   OF  METHODOLOGY 
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BLOOD SAMPLE COLLECTION  
 5  ml of  peripheral  blood  was  obtained  by  direct  venipuncture  
using disposable  syringe from the antecubital vein of each subject. The 
samples were immediately  transferred into EDTA containing vacutainer 
tubes. The vacutainer tubes were kept in  thermos ice box and transferred 
immediately to the Department Endocrinology   , IBMS, Taramani where 
the buffy coat was separated and  stored at  –20°C  until     isolation of 
DNA was done. 
DNA ISOLATION AND PURIFICATION 
 The   phenol  chloroform  method of DNA isolation was used in this 
study.  
 This  frequently used method for DNA isolation removes proteins 
and other cellular components   from nucleic acids, resulting   in   relatively   
pure   DNA  preparations.  
I. PRINCIPLE 
 The concept of isolation of DNA is that all the other components of 
the cell and  chromatin are removed using suitable methods to leave behind 
the DNA. In general the  isolation of DNA from mammalian tissues follow 
four different steps. 
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 1. Lysis of cells with a detergent like sodium dodecyl sulphate 
(SDS). 
 2. Digestion of proteins with enzymes (Proteinase – K). 
 3. Extraction of DNA by phenol chloroform method.  
 4. Precipitation of DNA with isopropyl alcohol or 100% ethanol. 
II. REAGENTS AND THEIR FUNCTIONS 
1. RBC  Lysis  Buffer 
 Ammonium chloride – 155mM (8.29g) 
 EDTA    – 0.1mM (1.00g) 
 NaHCO3     – 12mM  (0.034g) 
 pH  adjusted  to 7.4  with 1M HCl or NaOH,  made  upto 1000 ml  
with distilled water.  Autoclaved  and stored  at room temperature.  
 The  RBC  lysis  buffer   was  used  to  lyse  the erythrocytes. 
2. SE Buffer/WBC Lysis  Buffer 
 Na2EDTA – 25mM   (8.41g) 
 NaCl         – 200mM (11.69g) 
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 pH  adjusted  to 8.0 with 1M  NaOH,  made  upto 1000 ml with 
distilled water,   autoclaved  and stored  at room temperature. 
3. Proteinase K (10 mg/ml) 
 Proteinase K  - 100 mg 
 TE   - 10 ml 
 100 mg  Proteinase K  dissolved in 10 ml TE for  30 min  at   room  
temperature  and  stored at -20°C.    Proteinase  K  is  the  enzyme  
commonly employed  for digestion of proteins.  It is a highly active 
protease purified from the mold  Tritirachium  album.  The digestion with  
proteinase K is usually carried out in presence  of   EDTA  because   EDTA  
inhibits the  action  of Mg2+ ion  dependent nucleases  which  otherwise  
can  digest  the  DNA. 
4. Sodium dodecyl sulphate (SDS) 10% 
 SDS - 10 gram 
 Water  added  to make up to 100 ml, stirred  on  a  magnetic stirrer, 
filtered and   stored  at room temperature. 
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 SDS is the commonly used detergent for DNA isolation. It ruptures 
the cell wall and nuclear membranes to release the contents.  Furthermore,  
it  also  denatures  proteins present  in  the  sample. 
5. Phenol (Saturated, pH 8) 
 Phenol is used to extract the DNA from the solution. In alkaline pH it 
extracts the  DNA to the aqueous phase, which is collected for further 
purification. This will prevent the  contamination of DNA with RNAs. In 
neutralor acidic pH phenol extracts RNA to aqueous  phase. Hence, the pH 
of phenol is very important for this step.   The pH  of  phenol  should  be  
maintained above 7.8 as all eukayotic RNA with  poly-A  tails  dissolve in 
alkaline phenol  but  in the acid range the DNA will partition   into  organic  
phase.  
6. Phenol: Chloroform : Isoamyl alcohol mixture 
 Phenol: Chloroform: Isoamyl alcohol mixture prepared by mixing  
25 parts of Phenol, 24 parts of Chloroform  and 1 part of Isoamyl alcohol. 
The denaturation of proteins is mainly achieved through the activity of 
chloroform. It  causes surface denaturation of proteins and also helps in 
removal of fats from the sample.  
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 Chloroform also eliminates any traces of phenol as phenol can cause 
phosphodiester breakage. Mixture of phenol and chloroform is also useful 
for the removal of protein from  nucleic acid samples.  Because of the 
presence of proteins in the solution, the chance of foaming is more for the 
solution at the time of phenol: chloroform extraction. The action of isoamyl 
alcohol  is to reduce the foaming and to maintain the stability of layers after 
centrifugation of  deproteinised solution. 
7. Isopropyl Alcohol 
 The action of isopropyl alcohol is to precipitate the DNA leaving 
RNA and polysaccharides in the solution.  
8. 70% Ethanol 
 Ethanol  - 70 ml 
 Distilled water - 30 ml1 
 It removes residual salt and moisture in the precipitated DNA. 
9. Tris-EDTA (TE) Buffer (pH - 8.0) 
 Tris base  - 1.2114 gram 
 EDTA  - 0.0372 gram 
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 Dissolved  in 900 ml distilled water and  the pH  adjusted  to 8. The 
volume made  up  to 1000 ml. Filtered , autoclaved  and stored   at 4oC.  
Ideal  buffer  to  store  the  DNA. 
III. PROCEDURE 
 5ml of  whole  blood  was taken and spun at 3500rpm for 20min at 
25°C.  
 Buffy coat  was removed carefully and transfered to a new 2.0 ml 
eppendorf tube. 1ml   of   1x RBC lysis  buffer was added to the buffy coat, 
vortexed, mixed well and incubated for 15 min at 37°C  followed by a spin 
at 3500rpm for 15 min at room temperature.  The supernatant was  
discarded, the pellet was dislodged and washed 2 or 3 times with 1ml RBC 
lysis buffer  (repeat of step 2) until a half white pellet appears. The pellet 
was then dislodged by  tapping to which 500μl of SE (WBC lysis) buffer, 
5μl ProteinaseK (final concentration  200μg/ml) and  25μl  (final 
concentration 0.5%)   10% SDS   was  added  and  incubated  in  water bath 
at 37°C for overnight or 55°C for 3 hours.  Equal volume of Phenol: 
Chloroform: Isoamylalcohol (25:24:1) to the lysate was added and intensely 
mixed well by inverting the  tube until it turns to milky white in colour. The 
samples were spun at 10,000 rpm for 15min  at room temperature. The 
upper aqueous phase alone was carefully collected  with the  help of wide 
  23
bore tips without disturbing the other layers and transferred  to a new tube.  
To  this aqueous phase 2.5 volumes of chilled absolute ethanol was added 
and the tubes were  inverted gently for several times. The DNA will be 
visible like a thread and will assume the  shape of a cotton ball. The DNA 
was transferred to an  eppendorf  tube  already  containing  1ml of 70% 
ethanol and spun at 12,000g for 10 min at 4°C. The Ethanol was discarded  
and the pellet is air-dried in a sterile place for 3 hours to remove any trace 
of residual ethanol.  
 Appropriate amount of 1X TE was added according to the size of the 
pellet, allowed  to dissolve and stored at 4°C. 
QUALITY CHECK  &  QUANTIFICATION OF DNA 
 The integrity of the DNA was assessed by running it in 0.7% 
Agarose gel. Further the  quantification and quality check of DNA was 
performed by subjecting the DNA to   spectrophotometry. 
I. PRINCIPLE 
 The concept of quality check of DNA is to find out the purity of the 
extracted  DNA.  The extracted DNA may contain impurities like phenol, 
proteins and others. The integrity of   the DNA is  checked  by  agarose  gel  
electrophoresis. 
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 The DNA is mixed with  loading dye  and  run electrophoretically  
on  0.7%  agarose gel  in TAE buffer, the  high molecular weight DNA  
appeared  as  sharp  band without   smearing. 
II. REAGENTS  
1) TAE buffer (10x) 
 Tris base   - 48.4 gram 
 Glacial acetic acid  - 11.42 ml 
 0.5 M EDTA (pH 8.0) - 20 ml 
 Distilled  water  added  to make up to 1000 ml 
 Autoclaved  and stored  at room temperature. 
2. Gel loading dye – Type III (6x) 
 Bromophenol blue   - 0.25% (w/v) 
 Xylene cyanol FF  - 0.25% (w/v) 
 Glycerol in water  - 30% (v/v) 
 Stirred  well  and stored  at 4oC. 
 
  25
3. Ethidium bromide 
 Ethidium bromide   - 10 mg 
 Distilled water   - 1 ml 
 Mixed  well  to ensure that the dye has dissolved completely.  The 
tube wrapped  in   aluminum  foil and  stored  at room temperature. 
III. PROCEDURE FOR AGAROSE GEL ELECTROPHORESIS 
1. 0.7% Agarose Gel preparation 
•  0.7 gram of agarose weighed and transferred into a 250 ml conical 
flask. 
• 100 ml of 0.5x TAE buffer was added to it, stirred well and melted 
on a  magnetic   stirrer cum hot plate until the agarose dissolves 
completely. 
• The appropriate sized gel tray and comb was washed and wiped with 
70% Ethanol.  The gel tray was placed inside the casting unit. The 
comb was placed on the gel  tray and left on an even surface. 
• After the agarose cools down to hand bearing temperature, 5 μl of 
ethidium  
bromide was added and mixed well. It was poured on the gel tray 
and allowed to polymerize. After polymerization the comb is 
removed  gently. 
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2. Preparation of sample and loading 
• The gel tray was removed from the casting unit and the tray placed in 
the electrophoresis tank. 
• 0.5x TAE buffer was poured into the tank until the gel gets 
immersed.  
• 2 μl of each DNA sample was  taken and mixed with 2μl of 6x 
loading dye and  8ml  of  sterile  double distilled water. 
• The DNA samples were loaded into the wells. 
•       The electrodes were connected. 
• The power was switched ON, set at 100 V. 
• As the DNA is negatively charged, it will migrate towards the anode. 
3. Visualizing the DNA 
• When the bromophenol blue dye was in the middle of the gel, the 
power was  switched OFF. 
• The gel was taken to the transilluminator and observed under UV 
and documented. 
• The good high molecular weight  DNA will appear as sharp band 
without smearing.  
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DNA  VISUALISED  ON  GEL 
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IV.  PROCEDURE FOR SPECTROPHOTOMETRY 
 The nucleic acid sample was analysed at 260nm and 280nm by 
using Nanodrop Spectrophotometer (Thermo scientific, Germany). The 
concentration and purity of the   sample  was  analysed using  the  
following  formula, 
 
CONCENTRATION OF DNA: 
Concentration  of  double  stranded  DNA  sample  (μg/μl)  = A260 
x 50 
 
PURITY OF DNA: 
Pure  DNA =  A260 /A280 ≥ 1.8 
< 1.8 indicates protein and phenol contamination 
>2.0 indicates the possible contamination with RNA 
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PRIMERS: 
 The  PRIMERS   were   commercially   procured.   The  forward  
and  Reverse  Sequences  of   the  Primers  for  XPD and  XRCC1  Exons  
are  given  below  
PRIMERS  FROM   XPD  EXON 23 
FORWARD   5’-CAGGTGAGGGGGACATCTGG-3’ 
REVERSE   5’-CTCTCCCTTTCCTCTGTTCTCTGC-3’ 
 
PRIMERS    FROM   XRCC1  EXON 10 
FORWARD   5'- TGCTTTCTCTGTGTCCACTATGCTGC-3' 
REVERSE   5'- TCTGATAAGCAGGCTTCACAGAGCC-3' 
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Components  of  10 μl  PCR  reaction  mix 
Contents Volume Final concentration 
10 X PCR buffer II  
(Applied Biosystems (ABI), USA) 
1 µl 1X 
25mM MgCl2  
(ABI, USA) 
1 µl 2.5 mM 
2.5mM dNTP mix  
(TAKARA, Japan) 
0.8 µl 0.2 mM 
2 µM Forward Primer 0.5 µl 100 nM 
2 µM Reverse Primer 0.5 µl 100 nM 
(ABI, USA)   
5U/µl AmpliTaq ®DNAPol 0.05 µl 0.25 U/reaction 
Template DNA(100ng/µl) 1 µl 100 ng/reaction 
Sterile distilled water 5.15 µl - 
Total reaction volume 10 µl - 
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POLYMERASE  CHAIN  REACTION  
PCR    thermal cycle  (XRCC 1  EXON  10  AND  XPD  EXON  23) 
 
STEPS TEMPERATURE TIME 
Initial Denaturation 94 deg celcius 5 min 
Denaturation 94  45 sec 
Annealing 63 1 min cycle ( 29 
cycles) 
Extension 72 1 min 
Final extension 72 5 min 
 
Hold  at  4  deg  celcius.   
  After the completion of the thermal cycles, the PCR product was 
resolved on 2% Agarose  gel  in  Mupid-ex  electrophoresis tank 
(TAKARA, Japan), and  the amplification was visualized and 
documented using UVP- UV Trans-illuminator. 
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PCR  ANALYSIS 
 
PCR- RFLP: 
 The  PCR  Fragment  was  digested  by  the enzyme  MboII , which 
digests the 733 bp fragment  of XPD  Exon 10 
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Enzyme  Msp I   digests  the  PCR  fragment  of  XRCC 1 
 
 
Components for 20 μl RFLP Reaction mix 
Contents Volume 
Final 
concentration
PCR product 10 µl - 
10X NE Buffer 4 (NEB Inc– 
USA) 
2 µl 1 X 
10X BSA (NEB Inc- USA) 2 µl 1 X 
MspA1I (10 U/µl) (NEB Inc- 
USA) 
0.2 µl 2 U/reaction 
Sterile distilled water 5.8 µl - 
Total reaction volume 20 µl - 
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RFLP reaction conditions 
1. 37°C- 16 hours/Overnight 
2. 4°C- ∞ 
  After the completion of the restriction digestion, 20 µl of the digest 
product and 2 µl of 6X DNA gel loading dye was mixed well and 
resolved by electrophoresis in Mupid-ex electrophoresis tank (TAKARA, 
Japan) in 2.0% agarose gel. Theresolved gel was visualized using UVP- 
UV Trans-illuminator.   
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OBSERVATION AND RESULTS 
 
STATISTICAL ANALYSIS 
Statistical  analysis  was  done  using  the  SPSS Software. 
 The  association between  XRCC1 and  XPD  Polymorphisms  and   
risk  of  Ca.Prostate  was  determined  by  calculating  the  Odds Ratio 
(OR)  at 95%  Confidence  interval( CI). 
 Any  possible  effect modification by age was also evaluated  by 
stratifying by age at  diagnosis (<65 versus >65). In addition, to 
investigate the potential effect of genotype  on   disease   aggressiveness,  
stratified the analyses  of  the cases’   clinical   characteristics at diagnosis   
done.The  cancer  risk   was  also  analysed  by  stratifying  the  patients  
based  on  Gleason score  and  Sr.PSA  levels. 
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TABLE - 1 
ASSOCIATION OF  XRCC 1  
GENOTYPE AND PROSTATE CANCER 
GENOTYPE 
CASES ( %)
n- 25 
CONTROLS(%)
n - 25 
OR 
(95% CI) 
P 
Arg/Arg 4 ( 16%) 
10 ( 40%) 
 
0.29 
(0.06 – 1.27) 
0.115 
Arg/Gln 15( 60%) 7 (28%) 
3.86 
(1.02 – 
15.17) 
0.046 
Gln/Gln 6 ( 24%) 
8  ( 32%) 
 
0.67 
(0.16 -  2.74) 
0.753 
 
 The  Association  of  XRCC 1 genotype and  Prostate  cancer  was  
assessed  in  25  Prostate  cancer  patients. 4 (16%)  were  Arg/Arg, 15 
(60%)  were  Arg/Gln  and 6 (24%)   were  Gln/Gln.   Among  the  25 
controls,  10 (40%)  were  Arg/Arg, 7(28%)  were  Arg/Gln,  8 (32%)  
were  Gln/Gln. 
With  Arg/Arg  as   the  reference  genotype ,  the Odds Ratio (95%  
CI)  of  the Homozygosity  and  heterozygosity  of  the  Gln  allele  was  
assessed. It  was found  that   the  Arg/  Gln  genotype  was  found  to  
have statistically  significant association  with  Prostate  cancer ( p<0.05). 
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The  Arg/Arg  genotype  and  Gln/Gln genotype   did   not  have  a  
significant  association  with  Prostate  cancer. 
TABLE  - 2 
XRCC 1  GENOTYPE  AMONG  PROSTATE CANCER 
PATIENTS  AND  CONTROLS  STRATIFIED  BY  AGE 
GENOTYPE 
CASES 
(%) 
CONTROLS(%) OR  
( 95 % CI) 
P 
AGE < 65 YRS N- 10 N- 14 
Arg/Arg 2(20%) 5(35.7%) 
0.45   
(0.04 – 3.99) 
0.652
Arg/Gln 6(60%) 4(28.6%) 
3.75  
(0.51 –
31.14) 
0.211
Gln/Gln 2(20%) 5(35.7%) 
0.45  
(0.04 – 3.99) 
0.704
AGE ≥ 65 YRS N- 15 N- 11   
Arg/Arg 2(13.3%) 5(45.4%) 
0.18  
(0.02 – 1.62) 
0.169
Arg/Gln 9(60%) 3(27.2%) 
4.00  
(0.58 –
31.07) 
0.209
Gln/Gln 4(26.6%) 3(27.2%) 
0.97  
(0.12 – 7.74) 
1.000
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The  association of  XRCC 1  genotype  with Prostate  cancer  
patients based  on the   age  was  calculated. Among  the  subjects  less  
than 65 yrs, Arg/Arg  was  observed  in  20% and  35.7%, Arg/Gln  
observed  in  60% and  28.6%, Gln/Gln  observed in 20 % and  35.7%  of   
cases and controls respectively. Among  the  subjects more  than  65  yrs, 
Arg/Arg  was   observed  in  13.3%  and  45.4%, Arg/Gln  in  60%  and  
27.2%  , Gln/Gln  in  26.6%  and  27.2%  of   cases  and  controls  
respectively.  No  significant   association  was  observed  between  the  
genotypes  stratified  by  age  and  risk  of  Prostate  cancer.  
XRCC 1  GENOTYPE  AMONG  PROSTATE CANCER 
PATIENTS  AND  CONTROLS  STRATIFIED  BY  AGE 
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TABLE - 3 
ASSOCIATION OF  XRCC 1 GENE  WITH   
GLEASON SCORE IN PATIENTS 
GENOTYPE 
PATIENTS(%) 
OR 95% CI P 
GLEASON
SCORE≥7 
n- 12 
GLEASON
SCORE<7 
n-13 
Arg/Arg 2(16.6) 2(15.3) 1.10 
0.09 – 
14.18 
1.000 
Arg/Gln 8(66.6) 7(53.8) 1.71 
0.26 – 
11.92 
0.688 
Gln/Gln 2(16.6) 4(30.7) 0.45 
0.04 – 
4.10 
0.645 
 
 The  XRCC 1 genotype  distribution  based  on  the  Gleason score 
was  assessed. 
 Arg/Arg  genotype  was  seen  in   16.6% and  15.3% , Arg/Gln  
genotype  in 66.6% and 53.8%, Gln/Gln in  16.6%  and  30.7%  of  
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patients with Gleason score less than  7  and  more than  7 respectively. 
No  significant  association  between the genotypes and  Histologic  grade  
of  Prostate  cancer. Statistical assessment is limited by the small  number  
of  patients  in  each  group.  
TABLE - 4 
DISTRIBUTION  OF XRCC 1 GENOTYPE IN PATIENTS   
BASED  ON PSA LEVELS 
 
GENOTYPE 
PATIENTS(%) 
OR 95% CI P PSA ≥50 
ng/dl 
n-10 
PSA<50 
ng/dl 
n-15 
Arg/Arg 2(20) 2(13.3) 1.00 
0.13 –
21.44 
1.000 
Arg/Gln 6(60) 9(60) 1.00 
0.15 – 
6.91 
1.000 
Gln/Gln 2(20) 4(26.6) 0.69 
0.07 – 
6.38 
1.000 
 
 The  XRCC 1 Genotype  association  with  Prostate  cancer    based   
on  the Sr.PSA  levels  were  assessed. Arg/ Arg  genotype  was  observed 
in  20% and 13.3 % ,  Arg/Gln  in  60%  and  60%  , Gln/Gln  in 20% and  
26.6%  of  patients  with  Sr.  PSA  levels  of  more than 50 ng/ml  and  
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less than 50 ng/ml  respectively.  No   significant  association  was  
observed  between  the  genotypes  stratified    by   Serum PSA  levels  
and  Carcinoma  Prostate.    
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TABLE  5 
ASSOCIATION  OF  XPD  GENOTYPE  AND  
PROSTATE  CANCER 
GENOTYPE 
CASES ( 
%) 
n- 25 
CONTROLS(%)
n - 25 
OR 
(95% CI ) 
P 
Lys/Lys 9 ( 36%) 12  ( 48%) 
0.61 
(0.17 – 2.19) 
0.567
Lys/Gln 13( 52%) 5 (20%) 
4.33 
(1.06 – 
18.63) 
0.039
Gln/Gln 3( 12%) 
8(32%) 
 
0.29 
(0.05 – 1.49) 
0.172
  
 The  Association  of  XPD   genotype and  Prostate  cancer  was  
assessed  in  25  Prostate  cancer  patients . 9 (36%)  were  Lys/Lys , 
13(52%)  were  Lys/Gln  and 3 (12%)   were  Gln/Gln.   Among  the  25 
controls,  12 (48%)  were  Lys/Lys  , 5(20%)    were  Lys/Gln  , 8 (32%)  
were  Gln/Gln.With  Lys/Lys   as   the  reference  genotype ,  the Odds 
Ratio ( 95%  CI)  of  the Homozygosity  and  heterozygosity  of  the  Gln  
allele  was  assessed .It  was found  that   the  Lys /  Gln  genotype  was  
found  to  have  statistically  significant association  with  Prostate  cancer 
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( p<0.05). The  Lys/Lys  genotype  and  Gln/Gln genotype   did   not  
have  a  significant  association  with  Prostate  cancer.    
TABLE - 6 
XPD   GENOTYPE AMONG  PROSTATE CANCER PATIENTS  
AND  CONTROLS STRATIFIED  BY  AGE 
GENOTYPE 
CASES 
(%) 
CONTROL
S(%)  
OR 
95 % 
CI AGE < 65 
YRS 
N- 10 N- 14 
Lys/Lys 4(40%) 6(42.8%) 0.89 (0.13 – 6.25) 1.000 
Lys/Gln 5(50%) 3(21.4%) 3.67 (0.46 –32.64) 0.204 
Gln/Gln 1(10%) 5(35.7%) 0.20 (0.01 – 2.55) 0.339 
AGE ≥ 65 
YRS 
N- 15 N- 11   
Lys/Lys 5(33.3%) 6(54.5%) 0.42 (0.06 – 2.69) 0.426 
Lys/Gln 8(53.3%) 2(18.1%) 5.14 (0.64 –50.53) 0.157 
Gln/Gln 2(13.3%) 3(27.2%) 0.41 (0.04 – 4.13) 0.698 
 
 The  association of  XPD  genotype  with Prostate  cancer  patients  
based  on the  age  was  calculated. Among  the  subjects  less  than  65  
yrs, Lys/Lys  was  observed   in  40% and  42.8 % , Lys/Gln  observed  in  
50% and  21.4% , Gln/Gln  observed    in   10 % and  35.7%  of   cases  
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and  controls   respectively. Among  the  subjects more  than  65  yrs , 
Lys/Lys  was   observed  in  33.3%  and  54.5% , Lys/Gln  in  53.3%  and  
18.1%  , Gln/Gln  in  13.3%  and  27.2%  of   cases  and  controls  
respectively.  No   significant   association  was  observed  between  the  
genotypes  stratified  by  age   and  risk  of  Prostate  cancer.  
 
XPD     GENOTYPE   AMONG   PROSTATE   CANCER   
PATIENTS  AND  CONTROLS    STRATIFIED    BY  AGE 
` 
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TABLE - 7 
ASSOCIATION   OF   XPD GENE  AND  GLEASON  SCORE 
GENOTYPE 
PATIENTS(%) 
OR 95% CI P 
GLEASON
SCORE≥7 
n- 12 
GLEASON
SCORE<7 
n-13 
Lys/Lys 5(41.6) 4(30.7) 1.61 0.23 – 11.45 0.688
Lys/Gln 6(50) 7(53.8) 0.86 0.13 – 5.47 0.835
Gln/Gln 1(8.3) 2(15.3) 0.50 0.02 – 8.95 1.000
 
 The  XPD  genotype  distribution  based  on  the  Gleason score 
was  assessed. 
 Lys/Lys   genotype  was  seen  in   41.6% and  30.7% , Ly/Gln  
genotype  in  50% and  53.8%  , Gln/Gln in  8.3%  and  15.3%  of  
patients  with  Gleason  score less than   7  and  more  than  7   
respectively. There  was  no  significant  association  between  the    
genotypes  and  Histologic  grade  of  Prostate  cancer. Statistical  
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assessment  is    limited  by the  small  number  of  patients  in  each  
group.  
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TABLE - 8 
DISTRIBUTION OF XPD  GENOTYPE IN PATIENTS   
BASED  ON PSA LEVELS 
GENOTYPE 
PATIENTS(%) 
OR 95% CI P 
PSA ≥50 
ng/dl 
n-10 
PSA<50 
ng/dl 
n-15 
Lys/Lys 4(40) 5(33.3) 1.33 0.19 – 9.59 1.000 
Lys/Gln 5(50) 8(53.3) 0.88 0.13 – 5.79 1.000 
Gln/Gln 1(10) 2(13.3) 0.72 
0.02 – 
13.11 
1.000 
 
 The   XPD  Genotype  association  with  Prostate  cancer    based   
on  theSr.PSA  levels  were  assessed.  Lys/Lys  genotype  was  observed 
in  40% and 33.3 % ,  Lys/Gln  in  50%  and  53.3%  , Gln/Gln  in 10% 
and  13.3%  of  patients with  Sr.  PSA  levels  of  more than 50 ng/ml  
and  less than 50 ng/ml  respectively. 
 No   significant  association  was  observed  between  the  
genotypes  stratified  by   Serum PSA  levels  and  Carcinoma  Prostate.    
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DISCUSSION 
 The  Arg/ Gln   genotype   in   XRCC1  and  Lys/Gln   genotype  in  
XPD  were  found   in    60 %   and  52 %    of   Ca.Prostate    patients   
and   found  to  be statistically    significant  with  the  risk  of Prostate  
cancer. All  the  subjects  included  in  our  study  were  unrelated.  The  
other  genotypes  did  not  show  a  significant   risk  of   developing  
Ca.Prostate. 
 The  genotype  association  with  Ca.Prostate  based  on  the  age, 
Gleason  score and   Sr.PSA  was  not  found  to  be  statistically   
significant.  The  statistical   assessment  is  limited  by  the  small   
number of  patients .   
 Rybicki  et al   examined the XRCC1   codon 399 and XPD codons 
312 and 751 polymorphisms in   relation to prostate cancer risk in a large 
sample of primarily Caucasian sibships.  Only  the XPD  codon 312 Asn  
allele  showed  a  modest  association   with increased prostate cancer  
risk, 60%, when two copies of the allele were present.    Perhaps  more   
revealing,  however, was   the    potential interaction  between the XPD   
codon 312 Asn allele and the XRCC1 codon  399  Gln allele. When both 
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alleles were   present in their homozygous states, the risk for  prostate 
cancer increased  4.8-fold. 
 Only a   few studies of more common DNA repair genetic variants 
and  prostate cancer   risk exist in the literature. Xu et al. studied  18 
different genetic variants of  the DNA   repair enzyme gene hOGG1,   
involved   in base excision repair, and found  the   genotype  frequency of 
two sequence variants (11657A/G and  Ser326Cys)  was  significantly 
different between prostate cancer  cases and  controls. They also 
confirmed  the association with  the 11657A/G variant in a  family-based 
association study. Van  Gils et al 50  studied three genetic variants  in 
another base excision repair enzyme  gene, XRCC1, and found no 
association  between XRCC1 polymorphisms and prostate  cancer  when 
only comparing  genotype frequencies in cases and controls.  However,  
when they stratified the  study population by   intake of several different 
dietary  antioxidants, the more  common  XRCC1 codon  399 Arg/Arg   
genotype   was  associated  with   prostate  cancer in those with low 
vitamin E or lycopene intake.   
 Rybicki et al , on the other  hand, found the less common XRCC1 
codon   399 Gln/Gln    genotype to be a  potential modifying factor for 
prostate cancer risk associated with the XPD codon 312 Asn/ Asn 
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genotype. It is not inconceivable that interactions at the XRCC1 codon 
399 locus are dependent on genotype, with some genetic or  
environmental risk factors preferentially interacting with the Arg/Arg 
genotype and  others more likely to interact with the Gln/Gln genotype. 
The   unadjusted ORs for  the   XRCC1 codon 399 Gln/Gln genotype in 
the  study of van Gils et al.  was 0.77,  compared  with  Rybicki et al  OR 
estimate of 0.88. Previous studies of the XRCC1  codon  399 
polymorphism are equivocal with some finding increased  risk   for  the  
Gln   allele   but  others  finding  an  increased  risk  for  the  Arg  allele . 
Rybicki  et al  family-based  study  had  several strengths, which  include 
the   size   of   the  study population, the elimination of potential  bias due 
to population   genetic  substructure,  and full  utilization of sibship data 
(without parental genotypes) that were composed of numerous 
configurations including sibships with only affected  brothers.  
 The incorporation of genotypic information of unaffected  brothers 
for a common  disease such as prostate cancer  can also significantly 
increase statistical power 56. Another  advantage of   a  family-based   
design   concerns the    absence   of Hardy-Weinberg equilibrium in a 
control population   found for the XPD codon  312 polymorphism. 
Although this would be troublesome in a case-control  population, it   was  
less  of a concern in   Rybicki et al  family-based   study  because it could 
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be due   to  the association of this genotype with prostate cancer-affected 
brothers of these controls.  
 Despite the many advantages of   family-based population, several 
potential   disadvantages  also  exist including the potential for selection 
bias due to difficulty of enrolling multiple family members 57   and 
decreased statistical power compared  with case-control populations 
under  some circumstances 58, 59.   
 Rybicki et al  found, that  when stratifying  on family history,  the  
risk   associated   with   the   XPD codon 312   Asn/Asn   genotype was 
greater in siblings   with  a   negative  family  history,   which would 
suggest that the population  risk for this genotype may be greater   than   
reported. 
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CONCLUSION 
 The   XRCC 1 Arg/Gln   genotype  and  XPD  Lys/Gln   genotype  
were  significantly  associated   with  an  increased  risk  of  developing  
Prostate  cancer. 
 The  XRCC 1  and  XPD  genotypes  stratified   by  age,  grade  
and  Sr.PSA   levels  did   not   show  any  significant  risk  of  developing  
Prostate  cancer. 
 The  present  study  of  DNA Repair  gene  polymorphisms  
predicts  risk  of   developing  Prostate  cancer  and  would  enable  
identification of  genetically  predisposed  individuals.   
 
 
 
 
 
 
 
 MASTER CHART 
Patient Age (Yr) S.PSA (ng/ml) Diagnosis HPE Gleason Score
1 65 13.99 CA PROSTATE ADENOCARCINOMA 4 
2 67 5.16 BPH BPH 
3 56 7.36 CA PROSTATE ADENOCARCINOMA 5 
4 63 9.98 CA PROSTATE ADENOCARCINOMA 4 
5 77 9.77 CA PROSTATE ADENOCARCINOMA 3 
6 70 3.26 BPH BPH 
7 69 4.14 BPH BPH 
8 64 22.14 CA PROSTATE ADENOCARCINOMA 5 
9 80 89.36 CA PROSTATE ADENOCARCINOMA 8 
10 55 6.96 BPH BPH 
11 60 7.14 BPH BPH 
12 64 CONTROL   
13 63 2.76 BPH BPH 
14 83 122.41 CA PROSTATE ADENOCARCINOMA 9 
15 61 78.16 CA PROSTATE ADENOCARCINOMA 7 
16 60 156.42 CA PROSTATE ADENOCARCINOMA 8 
17 62 4.14 BPH BPH 
18 61 3.32 BPH BPH 
19 59 6.69 BPH BPH 
20 63 16.44 CA PROSTATE ADENOCARCINOMA 7 
21 63 CONTROL   
22 87 246.56 CA PROSTATE ADENOCARCINOMA 9 
23 65 7.24 BPH BPH 
24 56 2.14 BPH BPH 
25 70 3.67 BPH BPH 
 Patient Age (Yr) S.PSA (ng/ml) Diagnosis HPE Gleason Score
26 84 272.47 CA PROSTATE ADENOCARCINOMA 8 
27 72 5.17 BPH BPH 
28 62 CONTROL   
29 81 37.27 CA PROSTATE ADENOCARCINOMA 7 
30 67 4.24 BPH BPH 
31 61 CONTROL     
32 70 48.56 CA PROSTATE ADENOCARCINOMA 6 
33 61 19.96 CA PROSTATE ADENOCARCINOMA 4 
34 69 7.42 BPH BPH 
35 73 98.17 CA PROSTATE ADENOCARCINOMA 8 
36 77 72.74 CA PROSTATE ADENOCARCINOMA 8 
37 73 8.19 BPH BPH 
38 74 46.14 CA PROSTATE ADENOCARCINOMA 6 
39 62 3.27 BPH BPH 
40 69 89.86 CA PROSTATE ADENOCARCINOMA 8 
41 78 15.45 CA PROSTATE ADENOCARCINOMA 5 
42 64 CONTROL   
43 62 29.32 CA PROSTATE ADENOCARCINOMA 6 
44 72 CONTROL   
45 64 17.14 CA PROSTATE ADENOCARCINOMA 4 
46 74 4.12 BPH BPH 
47 71 104.42 CA PROSTATE ADENOCARCINOMA 8 
48 68 3.89 BPH BPH 
49 63 23.32 CA PROSTATE ADENOCARCINOMA 4 
50 76 36.16 CA PROSTATE ADENOCARCINOMA 5 
 
 
 PROFORMA 
NAME:   
 
AGE :  
 
ADDRESS:  
 
 
CONTACT  NUMBER: 
 
IP  NO./ OP NO.:                             
EXAMINATION: 
     -DIGITAL  RECTAL  EXAMINATION 
INVESTIGATIONS:  
- Sr.PSA 
- TRUS  GUIDED  BIOPSY 
STUDY  TYPE         :   Retrospective  study 
                                  Retrospective  analysis  of  Carcinoma  
     Prostate   patients  ,  BPH  and   age   
     matched  controls   done 
 
. 
 INCLUSION CRITERIA:   Patients  with TRUS  biopsy  proven   
     Carcinoma  prostate and   Controls  
      ( includes BPH  patients  and  age   
     adjusted  controls) 
METHOD: 
• Isolation  of   DNA  from  peripheral  blood   sample  
by  Phenol chloroform  method 
• DNA  Precipitation   and  purification 
• PCR  amplification of  DNA repair  genes. 
• Purification  of  PCR  Product. 
• PCR-RFLP 
• Analysis  of  the  association  of the Genotypes of  
XRCC 1  and  XPD   with  the  cases and  controls.   
STATISTICAL  ANALYSIS :  
 Statistical   analysis   done   using the SPSS   Software. The  Odds 
Ratio, Confidence  interval  and   P  value  assessed   for   association  
and  risk  of   Prostate  cancer   with  the   various   genotypes   of   XRCC 
1   and   XPD  Genes. 
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